Table 1 Clinical features of recipient/donor and laboratory results
Recipient Information | Donor Information | First SCL detection | Follow-up and outcomes | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Case | Sex | Agea | Primary disease | Sex | Ageb | Relationship with donor | Intervalc | CG analysis | Chimerism test | Intervald | Last CG analysis | Last Chimerism test | GVHD | Relapse | Outcome | |
Group I | 1 | F | 52 | CML + NMZL | F | n/a | Unrelated | 1 | //45,X,-X [3]/46,XX[17] | Donor 100 % | 12 | //45,X,-X [4]/46,XX[16] | Donor 100 % | Yes | Yes | Dead |
2 | M | 64 | CLL | F | n/a | Unrelated | 1 | 45,X,-?Y[3]/46,XY[5]//46,XX[3] | Recipient 72 %; donor 28 % | 41 | nuc ish(DXZ1,DYZ1)x1[381/400]//DXZ1x2)[19/400] | Recipient 67 %; donor 33 % | No | Yes | Dead | |
3 | M | 69 | CLL | F | 53 | HLA-identical, related | 19 | 45,X,-?Y[8]/46,XY[22]// | Recipient 82 %; donor 18 % | 33 | 46,XY,del(5)(q13q33)[10]/46,XY[8]//.nuc ish(DXZ1x1,?DZY1x0)[15/400]/(DXZ1,DYZ1)x1[310/400]//(DXZ1x2)[75/400] | NA | No | Yes | Dead | |
4 | M | 56 | CLL | F | 58 | HLA-identical, related | 2 | 45,X,-?Y[3]/46,XY[13]//46,XX[4] | Recipient 38 %; donor 62 % | 58 | 45,X,-Y[5]/45,X,-Y,del(13)(q12q14)[2]/46,XY,del(13)(q12q14)[2]/46,XY[11]// | Recipient 100 % | No | Yes | Dead | |
5 | F | 69 | CLL | M | n/a | Unrelated | 3 | //45,X,-Y[3]/46,XY[17] | Donor 100 % | 0 | NA | NA | Yes | No | Dead | |
6 | M | 44 | AML | F | n/a | Unrelated | 2.5 | //45,X,-X[3]/46,XX[17].//nuc ish(DXZ1x1)[27/400]/(DXZ1x3)[8/400]/(DXZ1x2)[365/400] | Donor 100 % | 5 | //nuc ish(DXZ1x1)[24]/(DXZ1x2)[376/400] | Donor 100 % | Yes | No | Dead | |
7 | F | 67 | AML | M | 72 | Unrelated | 42 | //45,X,?-Y[3]/46,XY[17].//nuc ish(DXZ1x1,DZY1x0)[30/400]/(DXZ1,DZY1)x1[370/400] | Donor 100 % | 66 | 46,XX,del(7)(q31q34),inv(12)(q22q24)[18]//46,XY[3] | NA | Yes | Yes | Dead | |
8 | F | 38 | Hodgkin lymphoma | F | 23 | Unrelated | 13 | //45,X,-X[4]/46,XX[16] | Donor 100 % | 11 | //45,X,-X[1]/46,XX[19] | Donor 100 % | No | No | ACR | |
9 | F | 26 | AML | M | 50 | HLA-haploidentical, related | 24 | //45,X,-Y[5]/46,XY[15] | Donor 100 % | 38 | //45,X,-Y[10]/46,XY[10] | Donor 100 % | No | No | ACR | |
Group II | 10 | F | 19 | AML | M | 42 | HLA-haploidentical, related | -2e | 45,X,-X,inv(9)(p12q13)[7]/46,XX,inv(9)(p12q13)[13].nuc ish(DXZ1x1)[91/400] | Donor 100 %f | 12g | //46,XY[20] | Donor 100 % | Yes | No | ACR |
11 | F | 66 | CLL | F | 64 | HLA-haploidentical, related | -1e | 45,X,-X,inv(9)(p12q13)[6]/46,XX,inv(9)(p12q13)[14] | Donor 100 %f | 54g | Complex karyotype with inv(9)(p12q13)// | Recipient 38 %; donor 62 % | Yes | Yes | Dead | |
12 | F | 58 | AML | F | 51 | HLA-haploidentical, related | -12e | 46,XX,t(8;21)(q22;q22)[14]/45,idem,-X[6] | Donor 100 %f | 13g | //46,XX[20] | Donor 100 % | No | No | ACR | |